Healthcare

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four...

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025...

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need...

Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG)

Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...

error: Content is protected !!